Lilly Diabetes Drug Jardiance Improves Heart Health

By | August 20, 2015

Scalper1 News

Big pharma Eli Lilly (LLY) and its partner Boehringer Ingelheim said Thursday that their diabetes drug Jardiance succeeded in lowering the risk of death from cardiovascular disease in a massive three-year study, sending Lilly stock up sharply. Detailed results are being held for a medical meeting on Sept. 17, but Eli Lilly and Boehringer did say the Empa-Reg Outcome trial, which included more than 7,000 participants in 42 countries, achieved its Scalper1 News

Scalper1 News